ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on ...

Core Insights - Clearside Biomedical, Inc. has appointed Dr. Glenn C. Yiu to its Scientific Advisory Board, enhancing its expertise in retinal disease treatment and suprachoroidal delivery methods [1][2] - Dr. Yiu is recognized for his contributions to the research and application of new delivery techniques for retinal diseases, particularly in age-related macular degeneration (AMD) [2][3] - The company is advancing its CLS-AX program, which is in Phase 2b clinical testing for wet AMD, and aims to expand its pipeline of therapies utilizing its patented SCS Microinjector [4][5] Company Overview - Clearside Biomedical, Inc. specializes in innovative delivery of therapies to the back of the eye through the suprachoroidal space (SCS) [4] - The SCS Microinjector allows for a non-surgical, repeatable procedure for targeted delivery of therapies to treat sight-threatening eye diseases [4] - The company's first FDA-approved product, XIPERE®, is available in the U.S. and is designed for suprachoroidal use [4] Dr. Glenn C. Yiu's Background - Dr. Yiu is a Professor of Ophthalmology at UC Davis and a board-certified vitreoretinal surgeon with extensive experience in translational research focused on retinal diseases [2][3] - He has pioneered techniques such as CRISPR-based genome editing for wet AMD and microneedles for suprachoroidal gene delivery [2][3] - Dr. Yiu has received numerous accolades for his research contributions and serves on various editorial boards and committees in the field of ophthalmology [3]

Core Insights - Clearside Biomedical, Inc. is hosting a virtual key opinion leader (KOL) event on July 24, 2024, focusing on the advancements in suprachoroidal drug delivery for retinal diseases [1][12] - The event will feature presentations from leading retinal specialists, including insights on the company's SCS injection platform and its applications in treating neovascular age-related macular degeneration (wet AMD) [3][12] Company Overview - Clearside Biomedical is a biopharmaceutical company specializing in the delivery of therapies to the back of the eye through the suprachoroidal space (SCS) [5] - The company's SCS Microinjector® allows for a non-surgical, repeatable procedure aimed at delivering various therapies to the macula, retina, or choroid, potentially improving vision in patients with serious eye diseases [5] - Clearside's lead product, CLS-AX, is currently in Phase 2b clinical testing for wet AMD, while its first product, XIPERE®, is already available in the U.S. through a commercial partner [5] Event Details - The KOL event will include a live question-and-answer session with retinal experts and Clearside senior management, providing a platform for discussing real-world experiences with suprachoroidal drug delivery [3][12] - Notable speakers include Dr. David M. Brown, Dr. Victor Chong, and Dr. Glenn C. Yiu, who will share their expertise and insights on the implications of the SCS technology in retinal treatments [3][8][12] Research and Development Focus - The event will highlight the broad applicability of the SCS technology and ongoing clinical programs, emphasizing potential future development opportunities for Clearside [12] - The company is also exploring partnerships to enhance its SCS injection platform with other ophthalmic therapeutic innovations [5]

Core Insights - Clearside Biomedical, Inc. is hosting a virtual key opinion leader (KOL) event on July 24, 2024, focusing on suprachoroidal drug delivery and its applications in treating wet age-related macular degeneration (AMD) [1][2] Company Overview - Clearside Biomedical is a biopharmaceutical company innovating the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) [8] - The company utilizes its patented SCS Microinjector® for targeted, non-surgical delivery of therapies to the macula, retina, or choroid, aiming to preserve and improve vision in patients with sight-threatening eye diseases [8] - Clearside's lead program, CLS-AX (axitinib injectable suspension), is currently in Phase 2b clinical testing for wet AMD [8] Event Details - The KOL event will feature presentations from leading retinal specialists, including David M. Brown, M.D., Glenn C. Yiu, M.D., Ph.D., and Victor Chong, M.D., MBA, followed by a live Q&A session [3][4][5] - The event aims to discuss the broad applicability of suprachoroidal drug delivery and ongoing clinical programs, as well as potential future development opportunities for Clearside [2][3] Expert Contributions - David M. Brown, M.D., is a prominent figure in retinal research, focusing on AMD and diabetic retinopathy, and holds multiple leadership roles in clinical research [4] - Glenn C. Yiu, M.D., Ph.D., is recognized for his work in ocular imaging technologies and gene editing related to retinal diseases, including pioneering studies on wet AMD [5] - Victor Chong, M.D., MBA, has extensive experience in retinal health and has held significant positions in leading pharmaceutical companies [6]

Core Insights - Clearside Biomedical, Inc. is advancing the delivery of therapies to the back of the eye through its proprietary suprachoroidal space (SCS®) injection platform, which offers significant advantages in treating retinal diseases [1][6][9] Group 1: Suprachoroidal Injection Technology - The SCS Microinjector® allows for targeted delivery of various therapeutics to the macula, retina, or choroid, potentially preserving and improving vision in patients with sight-threatening eye diseases [4][6] - The suprachoroidal injection method minimizes exposure and adverse effects on the anterior segment of the eye, enhancing bioavailability to the posterior segment [16] - The technology is designed to work with both established and new formulations of medications, providing flexibility in treatment options [4][6] Group 2: CLS-AX Development - CLS-AX (axitinib injectable suspension) is being developed as a long-acting therapy for neovascular age-related macular degeneration (wet AMD) and is currently in Phase 2b clinical testing [5][10] - Preclinical studies and a Phase 1/2a trial have shown that CLS-AX is well tolerated and has an excellent safety profile, with the potential for prolonged duration and targeted delivery [5][10] - The ongoing ODYSSEY trial is expected to provide topline data in Q3 2024, focusing on patients with confirmed, active disease and allowing for multi-dosing data [10] Group 3: Market Position and Collaborations - Clearside is the only company with an FDA-approved product for suprachoroidal use and is actively pursuing partnerships to expand its SCS injection platform [9][10] - The company has reported encouraging clinical data from its licensing partners, with multiple therapies in development targeting serious ophthalmic indications [9] - The successful application of suprachoroidal injections may extend beyond steroids to include angiogenesis inhibitors and gene therapies, broadening the scope of ophthalmic treatments [16]

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - "Clearside is leading the way in suprachoroidal delivery, including having the only FDA approved product for suprachoroidal use and a second program with an expected near-term clinical data readout for CLS-AX in the large wet AMD market," said Victor Chong, M.D., MBA, Chief Medical Officer of Clearside. "We believe that suprachoroidal delivery combined with the differentiated mechanism of action and high potency of axi ...

The publication, entitled, "Suprachoroidal Space Injection Technique: Expert Panel Guidance" was co-authored by 16 practicing retinal physicians led by Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, Houston, TX. The guidance was developed based on current published evidence and clinical experience. The panel established consensus on the rationale for SCS injection, including potential benefits relative to other intraocular delivery methods, and current best practices in patient preparation, pre- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 900 North Po ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Remy Bernarda - Investor Relations George Lasezkay - Chief Executive Officer Victor Chong - Chief Medical Officer Charlie Deignan - Chief Financial Officer Conference Call Participants Jon Wolleben - JMP Securities Operator Greetings, and welcome to the Clearside Biomedical First Quarter 2024 Financial Results and Corporate Update Conference Call. As a reminder, this conference call is being ...

Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -21.43%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced a loss of $0.08, delivering a surprise of 20%.Over the last four quarters, the company has ...